ATAI Life Sciences CBO Sahil Kirpekar departs; separation and consulting agreements finalized
ATAI Life Sciences N.V.
Sahil Kirpekar terminated as Chief Business Officer effective April 2, 2025; separation agreement signed April 24.
Separation provides up to $5,000 legal fee reimbursement, extended option exercise to Aug 14, 2025, $3,400 learning costs, $12,000 relocation, company computer retention.
Consulting agreement effective April 3 for transitional BD support through Dec 31, 2025; allows vesting of 50% of unvested options from Mar 2023 and Mar 2024 grants.
No replacement named; Kirpekar continues as consultant for business development transition.
Sahil Kirpekar’s employment as Chief Business Officer of atai Life Sciences US, Inc. (“atai US”) and its affiliates, including atai Life Sciences N.V. (the “Company”), terminated effective April 2, 2025.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Sahil Kirpekar was terminated as Chief Business Officer at ATAI Life Sciences N.V..
Action
terminated
Role
Chief Business Officer
Exact text from the filing
Sahil Kirpekar’s employment as Chief Business Officer of atai Life Sciences US, Inc. (“atai US”) and its affiliates, including atai Life Sciences N.V. (the “Company”), terminated effective April 2, 2025.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.